Table IV.

Exosomal proteins in the top three mortality cancer types.

A, Lung cancer
Author, year	Protein	Study design	Sample	Clinical significance	Approach	Performance	(Refs.)
Yamashita et al, 2017	EGFR	Case-control	Human plasma	Potential diagnostic biomarker for characterization of lung cancer	ELISA	Increase	(54)
Sandfeld-Paulsen et al, 2016	NY-ESO-1	Case-control	Human plasma	A strongly prognostic markers for poor survival of NSCLC	Microarray	Increase	(55)
Ueda et al, 2014	CD91	Case-control	Human serum	Diagnostic markers for ADC	ELISA Mass spectrometry	Increase	(56)
B, Liver cancer
Author, year	Protein	Study design	Sample	Clinical significance	Approach	Performance	(Refs.)
He et al, 2015	CAV1/CAV2/S100A4	Cell model	HKCI-C3, HKCI-8 MHCC97L	Enhancing the invasive and migratory abilities of non-motile MIHA cells	Western blot Mass spectrometry	Increase	(75)
Qu et al, 2016	HGF	Cell model Animal model	MHCC-97L, MHCC-97H BALB/c nu/nu mice	Improving sorafenib resistance of HCC cells	ELISA Western blot	Increase	(79)
C, Gastric cancer
Author, year	Protein	Study design	Sample	Clinical significance	Approach	Performance	(Refs.)
Zhang et al, 2017	EGFR	Patients Animal model Cell model	Human serum/tissue BALB/c-nu nude mice SGC7901	Promoting GC liver metastasis	ELISA Western blot	Increase	(86)
Li et al, 2015; Liu et al, 2016	CD97	Cell model	SGC-7901	Promoting GC cells proliferation and invasion	Western blot	Increase	(87,88)
Zhong et al, 2011	Hsp70, Hsp60	Patients	Heat-treated malignant ascites	Inducing a CTL response in vitro and involving in the promotion of DC maturation	Western blot	Increase	(89)

NSCLC, non-small-cell lung cancer; ADC, lung adenocarcinoma; MIHA, motile immortalized hepatocyte; HCC, hepatocellular carcinoma; CTL, cytotoxic T lymphocyte; DC, dendritic cell.